Palisade Bio Announces Completion Of Enrollment In LB1148 Dose Optimization Study; Topline Data Expected In Q3 2023
Portfolio Pulse from Happy Mohamed
Palisade Bio, Inc. (NASDAQ:PALI) has completed patient enrollment in its dose optimization study of LB1148. The company expects to release topline data in Q3 2023. The study aims to generate pharmacokinetic and pharmacodynamic data across multiple doses in healthy adult volunteers and determine if a different dosing protocol might enhance the risk profile while providing efficacy for the development program.
July 05, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Palisade Bio's completion of patient enrollment for its LB1148 dose optimization study is a positive development. The topline data, expected in Q3 2023, could potentially impact the company's stock depending on the results.
The completion of patient enrollment is a positive step for Palisade Bio's LB1148 study. However, the impact on the company's stock will largely depend on the topline data expected in Q3 2023. Positive results could boost the stock, while negative results could have the opposite effect.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100